Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The company expects the full year’s revenue to be ...

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest ...

What Happened? Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval ...

Medication company Viatris (NASDAQ:VTRS) reported in Q2 CY2025, but sales fell by 5.6% year on year to $3.58 billion. The ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Q2 2025 Earnings Call Transcript August 7, 2025 Viatris Inc. beats earnings expectations. Reported EPS is $0.62, expectations ...

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with ...